• Median Technologies highlighted commercial launch readiness for eyonis LCS, its AI software for lung cancer screening, following FDA 510(k) clearance.
• Median reported 2025 revenue of EUR 23.4 million.
• Backlog stood at EUR 76.6 million as of Dec. 31, 2025.
• Median completed up to EUR 61.4 million refinancing in summer 2025, including EUR 37.5 million European Investment Bank financing with EUR 18.5 million undrawn.
• Median cited a non-exclusive distribution agreement with Tempus to support U.S. and EU commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Median Technologies SA published the original content used to generate this news brief on April 09, 2026, and is solely responsible for the information contained therein.